Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
Follow AMGN
Amgen Inc. (AMGN) EBITDA
Amgen Inc.'s EBITDA for fiscal 2025 was $15.4B, up 18.7% from $13.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was $16.5B. Over the past ten years it has ranged from $10.6B (fiscal 2015) to $15.4B (fiscal 2025) — the current reading is the highest in ten years. Amgen Inc. ranks 8th of 20 Drug Manufacturers General companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $15.4B | 18.74% |
| FY2024 | $13.0B | 1.48% |
| FY2023 | $12.8B | (1.26%) |
| FY2022 | $13.0B | 17.63% |
| FY2021 | $11.0B | (13.37%) |
| FY2020 | $12.7B | 7.24% |
| FY2019 | $11.9B | (2.69%) |
| FY2018 | $12.2B | 2.36% |
| FY2017 | $11.9B | 0.24% |
| FY2016 | $11.9B | 12.49% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $4.6B | 22.32% |
| Mar 2026 | $3.8B | (1.82%) |
| Dec 2025 | $3.9B | (9.00%) |
| Sep 2025 | $4.2B | 5.90% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVO Novo Nordisk A/S compare | $26.5B |
| ABBV AbbVie Inc. compare | $25.6B |
| NVS Novartis AG compare | $22.5B |
| PFE Pfizer Inc. compare | $20.4B |
| AZN AstraZeneca PLC compare | $20.3B |
| AMGN Amgen Inc. | $16.5B |
| BMY Bristol Myers Squibb Company compare | $15.1B |
| MRK Merck & Co., Inc. compare | $13.7B |
| GILD Gilead Sciences, Inc. compare | $262.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement